Japan's Mebiopharm Becomes First Listing On Tokyo AIM's Market
This article was originally published in PharmAsia News
Mebiopharm of Japan became the first company listed on the Tokyo AIM equity market, begun two years ago to serve professional investors
You may also be interested in...
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?